Vogt–小柳–原田综合征继发青光眼1例
A Case of Glaucoma Secondary to Vogt-Koyanagi-Harada Syndrome
DOI: 10.12677/hjo.2024.134014, PDF, HTML, XML,   
作者: 刘俊巧, 卢嵩杰, 何昌铸, 薛富丽:成都中医药大学眼科学院,四川 成都;何 宇:成都市中西医结合医院眼科,四川 成都
关键词: 葡萄膜脑炎综合征青光眼Uveomeningoencephalitic Syndrome Glaucoma
摘要: Vogt–小柳–原田综合征是一种以双眼弥漫性渗出性肉芽肿性葡萄膜炎为特征,伴有听觉功能障碍、脑膜刺激征及皮肤毛发变白等眼外表现的自身免疫性疾病,青光眼是其最具破坏性的并发症之一,它会导致不可逆的视野缺损和视力丧失,因此准确识别眼压升高的原因,选择合适的降眼压方式才能及时挽救患者的视力。现将就诊于我院的1例Vogt-小柳-原田综合征继发青光眼患者进行报道。
Abstract: Vogt-Koyanagi-Harada Syndrome is an autoimmune disease characterized by diffuse exudative granulomatous uveitis in both eyes with extraocular manifestations such as auditory dysfunction, meningeal irritation signs, and whitening of the skin and hairs, etc. Glaucoma is one of the most devastating complications, leading to irreversible visual field defects and loss of vision, so accurately identifying the cause of elevated intraocular pressure (IOP) and choosing the right IOP-lowering modality is the only way to save a patient’s vision in time. We report a case of glaucoma secondary to Vogt-Koyanagi-Harada Syndrome in our hospital.
文章引用:刘俊巧, 卢嵩杰, 何昌铸, 薛富丽, 何宇. Vogt–小柳–原田综合征继发青光眼1例[J]. 眼科学, 2024, 13(4): 99-104. https://doi.org/10.12677/hjo.2024.134014

1. 引言

Vogt-小柳原田综合征(Vogt-Koyanagi-Harada Syndrome, VKHS)是一种以双眼弥漫性渗出性肉芽肿性葡萄膜炎为特征,伴有听觉功能障碍、脑膜刺激征及皮肤毛发变白等眼外表现的自身免疫性疾病,青光眼是其常见并发症之一。但既往关于VKH综合征继发青光眼的发病机制及治疗方式选择的报道不多,因此本文就一例VKH综合征继发青光眼患者入手,对此进行报道。

2. 临床资料

患者,男性,37岁,因“双眼红痛伴视物模糊1+年,加重1+月”入院。1+年前患者无明显诱因出现双眼眼红、眼痛,伴视物模糊、畏光、流泪,外院就诊后诊断为“双眼VKH综合征”,予全身及局部激素治疗后上述症状缓解。后开始出现双眼眼周皮肤及睫毛变白,外院复查时加用环孢素治疗。1+月前患者复查时发现双眼眼压升高,局部使用降眼压药物治疗无效,就诊于我院。患者既往身体状况良好,双眼屈光不正病史,无重大内科疾病,无传染性疾病,无眼部外伤史及手术史。专科检查:裸眼视力右眼0.25,左眼0.06。眼压右眼49 mmHg、左眼32 mmHg。双眼眼睑颞侧皮肤变白,睫毛变白,睑缘充血,结膜混合充血,角膜水肿,KP+,前房深度正常,瞳孔呈花瓣状,直径4 mm,对光反射消失,晶状体混浊,前表面色素沉着,眼底窥不清(见图1)。辅助检查:眼底照相可见双眼大片脱色素晚霞状改变(见图2)。OCT提示双眼视网膜色素上皮层点状突起,层间结构欠清(见图3)。视野提示右眼上方弓形视野缺损,MD值为−15.42 dB。因屈光介质欠清,双眼房角镜检查不清。UBM提示右眼前房中央深度约2.70 mm,房角未见异常;左眼前房中央深度约2.69 mm,房角未见明显异常(见图4)。诊断:1) 双眼继发性青光眼;2) VKH综合征。治疗:入院后予降眼压、抗炎、散瞳治疗,完善术前相关准备后先后行“左眼/右眼小梁切除−5 FU + 周边虹膜切除 + 瞳孔再造 + 玻璃体腔注射地塞米松”,继续抗炎、散瞳治疗,术后1周右眼视力0.3,眼压19 mmHg;左眼视力FC/50 cm,眼压13 mmHg,术后1月右眼视力0.1,眼压16 mmHg;左眼视力FC/30 cm,眼压18 mmHg,目前门诊继续随访。

Figure 1. Photograph of the anterior segment of both eyes

1. 双眼前节照片

Figure 2. Wide-angle fundus photography suggests “sunset glow” fundus of both eyes

2. 广角眼底照相提示双眼眼底呈晚霞状改变

Figure 3. OCT suggests punctate protrusions in the retinal pigment epithelium in both eyes with poorly defined interlayer structure

3. OCT提示双眼视网膜色素上皮层点状突起,层间结构欠清

Figure 4. UBM suggests that the central depth of the anterior chamber of the right eye is about 2.70 mm, the central depth of the left eye is about 2.69 mm, and anterior chamber angle is open in both eyes

4. UBM提示右眼前房中央深度约2.70 mm,左眼前房中央深度约2.69 mm,双眼房角开放

3. 讨论

VKH综合征是一种以双眼弥漫性渗出性肉芽肿性葡萄膜炎为特征,伴有听觉功能障碍、脑膜刺激征及皮肤毛发变白等眼外表现的自身免疫性疾病。它是我国常见葡萄膜炎的类型之一[1],好发于20~50岁的成年人中,无明显性别差异[2]。VKH综合征临床表现多样,1995年Moorthy等人将其分为4期,即前驱期、急性葡萄膜炎期、慢性期及慢性复发期[3]。2007年国内专家团队根据中国VKH综合征患者的长期随访观察提出了以下分期:前驱期、后葡萄膜炎期、前葡萄膜受累期及肉芽肿性前葡萄膜炎反复发作期[4]。本病例患者就诊时见双眼前节KP+,眼底呈晚霞状改变,OCT提示双眼RPE层点状突起,伴有双眼眼睑颞侧皮肤及睫毛变白,双眼眼压升高,属于国内分期的肉芽肿性前葡萄膜炎反复发作期。目前国际广泛应用的VKH综合征诊断标准是2001年发布的改良诊断标准(Revised Diagnostic Criteria, RDC) [5]。但鉴于其在临床应用中存在一些局限性,因此国内相关专家制定出更符合中国人群的诊断标准(Chinese Diagnostic Criteria for VKH Disease, CDCV) [6]。本病例患者既往无眼球穿透伤及内眼手术史,无其他眼病病史,全身情况无特殊,就诊时双眼前节见复发性肉芽肿性前葡萄膜炎表现,眼底可见明确的晚霞状眼底,因此符合中国VKH病诊断标准的晚期VKH综合征。本病需与以下疾病进行鉴别:1) 交感性眼炎:既往有眼球穿孔史和内眼手术史,双眼发病往往不同时,没有典型的疾病进展规律及全身症状。2) 眼内中枢系统淋巴瘤所致的伪装综合征:发病年龄多在60岁以上,常有神经系统症状,但无VKH综合征典型全身症状,对激素治疗不敏感,磁共振检查和眼组织活检有助于鉴别诊断。目前,VKH综合征的治疗首选糖皮质激素[7],一般选用泼尼松口服,初始剂量为1.0~1.2 mg/(kg/d),根据炎症情况逐渐减量,疗程在1年左右。对于糖皮质激素难以控制或反复发作的炎症则需要联合一种或以上的免疫抑制剂。局部需要使用睫状肌麻痹剂,以解除睫状肌痉挛,改善血液循环,减轻炎症反应,预防虹膜后粘连而引起眼压升高。对于眼前节有炎症的患者,应使用糖皮质激素滴眼液,使用频率应根据炎症反应轻重进行动态调整。对于眼后节顽固性炎性反应患者,可考虑玻璃体腔内注射缓释长效糖皮质激素。

既往报道显示VKH病继发高眼压或青光眼的比率在15.8%~62% [8]-[10]。国内一项大规模研究结果显示,在平均25个月的随访中,我国1457名VHK综合征患者的2914只眼中有695只眼(23.9%)出现高眼压或青光眼[10]。VKH综合征继发高眼压或青光眼可以分为开角和闭角两种类型,其中以开角型更为常见,研究显示其比率达49.4%,其中最常见的原因是炎症[10]。炎症发生时炎性细胞浸润、蛋白质、碎片、纤维蛋白、炎性沉淀物以及小梁网肿胀都会导致小梁网机械性阻塞[11],Rho激酶等介质导致小梁内皮收缩,功能障碍从而引起房水流出受阻,眼压升高[12]。此外,有报告称炎性细胞释放的细胞因子会进一步加剧炎症并可能刺激房角形成新生血管,在慢性葡萄膜炎中小梁网或Schlemm管瘢痕形成和闭塞或房角纤维血管膜增生是导致房水流出受阻的主要原因[13]。研究显示任何病因引起的急慢性葡萄膜炎的眼中有13%~62%对类固醇有反应[14]-[16]。皮质类固醇会使糖胺聚糖在小梁网中沉积,并抑制小梁内皮细胞的吞噬作用及某些前列腺素的合成,因此影响小梁网的生化和形态学改变而增加房水流出的阻力[13]。闭角型青光眼的主要机制包括周边虹膜前粘连导致房角闭合以及广泛后粘连引起瞳孔阻滞,虹膜膨隆,阻塞房角[9]。此外还有一类患者以急性闭角型青光眼为VKH综合征的首发表现,其发生机制是炎症引起睫状突肿胀前旋,推动周边虹膜前移,堵塞房角;也可能是脉络膜积液使得睫状体向前旋转,从而使睫状小带和晶状体向前摆动从而出现瞳孔阻滞和前房变浅[17] [18]。临床上应判断患者眼压升高原因,及时准确地选用相应治疗方案,避免患者视力进一步受损。对于炎性反应引起的高眼压,应该在积极抗炎散瞳的同时联合降眼压药物[6] [13]。激素引起的眼压升高应尽早停止全身皮质类固醇的使用[6]。表现为急性闭角型青光眼的VKH病患者,激光周边虹膜切开术并不能降低其眼压[19],反而在得到皮质类固醇治疗后能够有效缓解[20] [21],因此与原发性闭角型青光眼的鉴别很重要。多数患者通过上述药物治疗能够控制眼压,但依旧有部分患者需要进行激光或手术治疗[8] [10] [21]。针对广泛后粘连引起瞳孔阻滞的情况,手术周边虹膜切除术有更高的成功率[10] [21]。小梁切除术通常可以成功控制眼压,但后期炎症复发可能导致滤过泡失败,因此联合抗增殖药物可提高其手术成功率[22]。小梁切除术联合抗增殖药物治疗葡萄膜炎性青光眼在1年时完全或基本成功率达到78% [23]。本病例患者长期口服糖皮质激素,就诊时双眼前节及后节仍存在炎症表现,UBM提示双眼房角开放,积极降眼压药物治疗后控制欠佳,因此采取小梁切除联合抗增殖药物及玻璃体腔药物注射皮质类固醇。后粘连是VKH病患者继发青光眼的危险因素[10],因此联合周边虹膜切除术以便更好地控制眼压。

总之,临床上遇到葡萄膜炎患者时应关注患者全身症状及体征,积极询问既往病史,若符合VKH综合征诊断标准,则要及时规范化使用糖皮质激素或联合免疫抑制剂治疗以减少并发症的发生。一旦发现患者眼压升高,应当积极寻找其原因,选择更为合适的方式尽快控制眼压,挽救患者视力。

参考文献

[1] Hao, T., Yang, L., Li, B., Chen, X., Li, D. and Liu, X. (2020) Epidemiology of 2000 Chinese Uveitis Patients from Northeast China. British Journal of Ophthalmology, 105, 317-321.
https://doi.org/10.1136/bjophthalmol-2020-316256
[2] Du, L., Kijlstra, A. and Yang, P. (2016) Vogt-Koyanagi-Harada Disease: Novel Insights into Pathophysiology, Diagnosis and Treatment. Progress in Retinal and Eye Research, 52, 84-111.
https://doi.org/10.1016/j.preteyeres.2016.02.002
[3] Moorthy, R.S., Inomata, H. and Rao, N.A. (1995) Vogt-Koyanagi-Harada Syndrome. Survey of Ophthalmology, 39, 265-292.
https://doi.org/10.1016/s0039-6257(05)80105-5
[4] Yang, P., Ren, Y., Li, B., Fang, W., Meng, Q. and Kijlstra, A. (2007) Clinical Characteristics of Vogt-Koyanagi-Harada Syndrome in Chinese Patients. Ophthalmology, 114, 606-614.E3.
https://doi.org/10.1016/j.ophtha.2006.07.040
[5] Read, R.W., Holland, G.N., Rao, N.A., Tabbara, K.F., Ohno, S., Arellanes-Garcia, L., et al. (2001) Revised Diagnostic Criteria for Vogt-Koyanagi-Harada Disease: Report of an International Committee on Nomenclature. American Journal of Ophthalmology, 131, 647-652.
https://doi.org/10.1016/s0002-9394(01)00925-4
[6] 中华医学会眼科学分会眼免疫学组, 中国医师协会眼科医师分会葡萄膜炎与免疫学组. 中国福格特-小柳-原田综合征临床诊疗专家共识(2023年) [J]. 中华眼科杂志, 2023, 59(7): 518-525.
[7] 黄果, 杨培增. Vogt小柳原田综合征的治疗进展[J]. 国际眼科杂志, 2017, 17(6): 1082-1086.
[8] Pandey, A., Balekudaru, S., Venkatramani, D.V., George, A.E., Lingam, V. and Biswas, J. (2016) Incidence and Management of Glaucoma in Vogt Koyanagi Harada Disease. Journal of Glaucoma, 25, 674-680.
https://doi.org/10.1097/ijg.0000000000000400
[9] Veerappan, M., Fleischman, D., Ulrich, J.N., Stinnett, S.S., Jaffe, G.J. and Allingham, R.R. (2016) The Relationship of Vogt-Koyanagi-Harada Syndrome to Ocular Hypertension and Glaucoma. Ocular Immunology and Inflammation, 25, 748-752.
https://doi.org/10.1080/09273948.2016.1189578
[10] Yang, P., Wang, C., Su, G., Pan, S., Qin, Y., Zhang, J., et al. (2020) Prevalence, Risk Factors and Management of Ocular Hypertension or Glaucoma in Patients with Vogt-Koyanagi-Harada Disease. British Journal of Ophthalmology, 105, 1678-1682.
https://doi.org/10.1136/bjophthalmol-2020-316323
[11] Moorthy, R.A.S., Mermoud, A.N., Baerveldt, G., Minckler, D.S., Lee, P.P. and Rao, N.A. A. (1997) Glaucoma Associated with Uveitis. Survey of Ophthalmology, 41, 361-394.
https://doi.org/10.1016/s0039-6257(97)00006-4
[12] Rao, P.V., Deng, P.F., Kumar, J. and Epstein, D.L. (2001) Modulation of Aqueous Humor Outflow Facility by the Rho Kinase-Specific in-Hibitor Y-27632. Investigative Ophthalmology & Visual Science, 42, 1029-1037.
[13] Siddique, S.S., Suelves, A.M., Baheti, U. and Foster, C.S. (2013) Glaucoma and Uveitis. Survey of Ophthalmology, 58, 1-10.
https://doi.org/10.1016/j.survophthal.2012.04.006
[14] Sharon, Y., Friling, R., Luski, M., Campoverde, B.Q., Amer, R. and Kramer, M. (2016) Uveitic Glaucoma: Long-Term Clinical Outcome and Risk Factors for Progression. Ocular Immunology and Inflammation, 25, 740-747.
https://doi.org/10.1080/09273948.2016.1255341
[15] Merayo-Lloves, J., Power, W.J., Rodriguez, A., Pedroza-Seres, M. and Foster, C.S. (1999) Secondary Glaucoma in Patients with Uveitis. Ophthalmologica, 213, 300-304.
https://doi.org/10.1159/000027443
[16] Shrestha, S., Thapa, M. and Shah, D.N. (2013) Pattern of Intraocular Pressure Fluctuation in Uveitic Eyes Treated with Corticosteroids. Ocular Immunology and Inflammation, 22, 110-115.
https://doi.org/10.3109/09273948.2013.824106
[17] Kishi, A., Nao-i, N. and Sawada, A. (1996) Ultrasound Biomicroscopic Findings of Acute Angle-Closure Glaucoma in Vogt-Koyanagi-Harada Syndrome. American Journal of Ophthalmology, 122, 735-737.
https://doi.org/10.1016/s0002-9394(14)70498-2
[18] Gohdo, T. and Tsukahara, S. (1996) Ultrasound Biomicroscopy of Shallow Anterior Chamber in Vogt-Koyanagi-Harada Syndrome. American Journal of Ophthalmology, 122, 112-114.
https://doi.org/10.1016/s0002-9394(14)71973-7
[19] Yao, J., Chen, Y., Shao, T., Ling, Z., Wang, W. and Qian, S. (2013) Bilateral Acute Angle Closure Glaucoma as a Presentation of Vogt-Koyanagi-Harada Syndrome in Four Chinese Patients: A Small Case Series. Ocular Immunology and Inflammation, 21, 286-291.
https://doi.org/10.3109/09273948.2013.792937
[20] Yang, P., Liu, X., Zhou, H., Guo, W., Zhou, C. and Kijlstra, A. (2011) Vogt-Koyanagi-Harada Disease Presenting as Acute Angle Closure Glaucoma at Onset. Clinical & Experimental Ophthalmology, 39, 639-647.
https://doi.org/10.1111/j.1442-9071.2011.02523.x
[21] Rathinam, S.R., Namperumalsamy, P., Nozik, R.A. and Cunningham, E.T. (1997) Angle Closure Glaucoma as a Presenting Sign of Vogt-Koyanagi-Harada Syndrome. British Journal of Ophthalmology, 81, 608a.
https://doi.org/10.1136/bjo.81.7.608a
[22] Forster, D.J., Rao, N.A., Hill, R.A., Nguyen, Q.H. and Baerveldt, G. (1993) Incidence and Management of Glaucoma in Vogt-Koyanagi-Harada Syndrome. Ophthalmology, 100, 613-618.
https://doi.org/10.1016/s0161-6420(93)31604-0
[23] Ceballos, E.M., Beck, A.D. and Lynn, M.J. (2002) Trabeculectomy with Antiproliferative Agents in Uveitic Glaucoma. Journal of Glaucoma, 11, 189-196.
https://doi.org/10.1097/00061198-200206000-00005